| Breast Adenocarcinoma studied in …STUDIED_INderived200 of 1,713show all (up to 200) |
|---|
| → studied in | NCT02883062Phase 2 · active not recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891171Phase 1 · active not recruiting Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058377Phase 3 · recruiting Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06505018NA · terminated Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06627712Phase 3 · recruiting SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06799065Phase 1/Phase 2 · recruiting First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847398NA · not yet recruiting Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05880160NA · completed Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06120283Phase 1 · recruiting BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586957Phase 1 · recruiting A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07152782Phase 2 · recruiting T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391774Phase 3 · recruiting Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Estrogen Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07698106Phase 1/Phase 2 · not yet recruiting Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02498613Phase 2 · active not recruiting A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04981119recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05528133Phase 2 · recruiting Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06393374Phase 3 · recruiting Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06841354Phase 3 · recruiting A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06966700Phase 3 · recruiting A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07066189NA · recruiting Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07419880Phase 2 · not yet recruiting Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842055completed AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04570956Phase 2 · terminated Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179303Phase 2 · recruiting Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Early Stage HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408856Phase 1 · recruiting CAN1012 in Pre-Malignant DCIS and LCIS · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07820228completed Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03387553early Phase 1 · completed HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07085767Phase 3 · recruiting Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07214532NA · recruiting Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07339176Phase 1/Phase 2 · recruiting Intratumoral N17350 in Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711847NA · recruiting Personalized Prone Immobilization for Accelerated Partial Breast Radiotherapy · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422794Phase 1 · recruiting Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528768Phase 2 · not yet recruiting HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07801508Phase 1 · recruiting A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02620852NA · recruiting Women Informed to Screen Depending on Measures of Risk (Wisdom Study) · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455270Phase 1 · completed G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04084730Phase 2 · recruiting Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Invasive Breast Carcinoma of No Special Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05550415Phase 2 · recruiting The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983432Phase 1 · recruiting Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04090398Phase 2 · active not recruiting Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04638751suspended ARGONAUT: Stool and Blood Sample Bank for Cancer Patients · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340541Phase 2 · recruiting Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705334Phase 1 · recruiting A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828652not yet recruiting Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07020117Phase 1 · recruiting A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297667Phase 1 · recruiting GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06353997Phase 2 · recruiting Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453620Phase 1 · active not recruiting Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05115474Phase 2 · recruiting Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05378464Phase 1 · suspended Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05809752Phase 1 · active not recruiting A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07513311NA · recruiting A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07702292Phase 2 · recruiting [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743723Phase 1/Phase 2 · not yet recruiting A Study of IOV-5001 in Adults With Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07796880Phase 2 · recruiting Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03077841Phase 2/Phase 3 · suspended Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191135Phase 2 · terminated Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04316117Phase 2 · active not recruiting Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05710328Phase 2 · active not recruiting Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06246968Phase 1 · recruiting A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07020806Phase 1 · recruiting [68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC) · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391956NA · recruiting Tier Palliative Care For Patients With Advanced Heart Failure or Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05306041Phase 2 · recruiting Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06033092Phase 2 · completed Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04251533Phase 3 · terminated Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638852Phase 2 · recruiting Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07652242Phase 1 · recruiting Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04030507NA · active not recruiting Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899908Phase 2 · recruiting Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05570253Phase 2 · recruiting A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633654Phase 3 · recruiting Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253871Phase 1 · recruiting A Phase 1/1b Study of IAM1363 in HER2 Cancers · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679360Phase 3 · recruiting A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00310180Phase 3 · active not recruiting Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03939897Phase 1 · active not recruiting Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02208375Phase 1 · active not recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04704661Phase 1 · active not recruiting Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05192798Phase 2 · recruiting Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06298084Phase 1/Phase 2 · recruiting Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06400472Phase 1 · recruiting A Study of Sofe-M in Participants With Selected Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465069Phase 1 · recruiting A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07300475Phase 1 · not yet recruiting Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04886531Phase 2 · recruiting Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05846789Phase 2 · recruiting Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06245889Phase 2 · recruiting PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06337084Phase 1 · active not recruiting Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06617169Phase 1 · active not recruiting Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635980Phase 2 · recruiting Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649331Phase 2 · recruiting Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06902311Phase 2 · recruiting Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07413939Phase 2/Phase 3 · recruiting RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02750826Phase 3 · active not recruiting Breast Cancer WEight Loss Study (BWEL Study) · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03317405Phase 1 · active not recruiting Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03893955Phase 1 · active not recruiting A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05837767NA · recruiting A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Invasive Breast Carcinoma of No Special Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05964504recruiting Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06557057recruiting Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06671912Phase 3 · suspended Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Estrogen Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07613151recruiting Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03401385Phase 1 · active not recruiting First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545122Phase 1 · recruiting A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02954874Phase 3 · active not recruiting Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05460273Phase 1/Phase 2 · active not recruiting A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05756166Phase 1/Phase 2 · terminated Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06460298Phase 1/Phase 2 · recruiting ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00433511Phase 3 · active not recruiting Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01272037Phase 3 · active not recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04427293Phase 1 · active not recruiting Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04677816Phase 2 · recruiting Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06068985Phase 2 · active not recruiting Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029399Phase 1 · recruiting A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768358Phase 4 · not yet recruiting Tucatinib Continuation Study · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06234488completed Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06414733Phase 1 · recruiting HER-2 B Cell Peptide Vaccine · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06949410Phase 1 · recruiting HER2 Vaccine for Locally Advanced Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07630961Phase 1 · recruiting Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02993068NA · suspended Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06123988NA · recruiting Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533826Phase 2 · recruiting TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577987Phase 1 · active not recruiting Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891833Phase 2/Phase 3 · recruiting A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383506Phase 1 · recruiting A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07729956Phase 3 · not yet recruiting A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07786428Phase 2 · not yet recruiting Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07787338Phase 2 · not yet recruiting SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788222Phase 2 · not yet recruiting Sacituzumab Govitecan and Q901 in Advanced TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06067503Phase 2 · recruiting Biomarkers to Detect Endocrine Therapy Resistance · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05501704Phase 2 · recruiting ETHAN - ET for Male BC · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084481Phase 1 · recruiting Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07596212Phase 1/Phase 2 · not yet recruiting BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07743190Phase 2 · recruiting A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04360941Phase 1 · active not recruiting PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05593094Phase 1/Phase 2 · active not recruiting A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441890Phase 2 · recruiting BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07321015Phase 2 · recruiting A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623369Phase 1 · recruiting A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269381Phase 1/Phase 2 · recruiting Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06027268Phase 2 · active not recruiting Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07191717Phase 2 · recruiting Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Estrogen Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07459673Phase 2 · recruiting HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01791478Phase 1 · completed BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Invasive Breast Carcinoma of No Special Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550494Phase 2 · active not recruiting Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04803084suspended Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04893109Phase 2 · recruiting ATEMPT 2.0: Adjuvant T-DM1 vs TH · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05545150Phase 2 · completed Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05919108Phase 2 · recruiting Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Invasive Breast Lobular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07115043Phase 1/Phase 2 · recruiting A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762703Phase 1/Phase 2 · not yet recruiting Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06144944Phase 3 · active not recruiting Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Low Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218303Phase 1 · recruiting Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06685796Phase 2 · completed A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910072Phase 2/Phase 3 · enrolling by invitation Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC） · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07182149Phase 1 · recruiting A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07544056Phase 2/Phase 3 · recruiting A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01266642Phase 2 · active not recruiting Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04332588Phase 1 · recruiting Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04861077early Phase 1 · recruiting Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895709Phase 1/Phase 2 · recruiting A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05340673Phase 1 · active not recruiting Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06358573Phase 2 · recruiting Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07341867Phase 1 · recruiting Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768436Phase 2 · recruiting A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04797299recruiting Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS) · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07737951NA · recruiting Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01208974NA · completed Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05985655Phase 1/Phase 2 · recruiting Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016738Phase 3 · active not recruiting OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06399757Phase 1/Phase 2 · active not recruiting A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762885Phase 3 · recruiting Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07762924Phase 2 · recruiting Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Breast Ductal Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03696030Phase 1 · active not recruiting HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04768426Phase 2 · recruiting Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06525766Phase 2 · recruiting Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | HER2-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06610097NA · withdrawn TNBC Gut Microbiota During Neoadjuvant Treatment · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07272642Phase 1 · not yet recruiting A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07760844Phase 3 · not yet recruiting An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05706129Phase 1/Phase 2 · recruiting A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05111561Phase 1 · recruiting Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07044310Phase 2 · recruiting 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Hormone Receptor-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07741968NA · recruiting A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer · condition mapped ONTOLOGY_EXACT · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07038369Phase 1 · active not recruiting A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07752550Phase 2 · not yet recruiting Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05581004Phase 1 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721248Phase 2 · active not recruiting STOP-HER2: Stopping Trastuzumab in HER2+ MBC · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06176261Phase 2 · recruiting DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs · condition mapped CURATED_BROADER · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06586047early Phase 1 · recruiting Breast Cancer PSMA PET · condition mapped ALIAS · 1,713 trials mapped (778 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |